Healio

Vtama cream 1% effective, safe for intertriginous plaque psoriasis treatment

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. 82.8% of patients treated with Vtama achieved the ...
Business Wire

Dermavant Presents Positive Results from Phase 4 Open-Label Trial of VTAMA® (tapinarof) Cream, 1% for the Treatment of Intertriginous Plaque Psoriasis in Adults at 43 rd ...

Intertriginous plaque psoriasis, also known as inverse psoriasis, affects approximately 20%–30% of individuals who have plaque psoriasis. The treatment for plaque psoriasis in intertriginous areas is ...
Business Wire

Dermavant to Present New Positive Data from Phase 4, Open Label Trial of VTAMA® (tapinarof) Cream, 1% for Intertriginous Plaque Psoriasis in Adults and Multiple Clinical ...

LONG BEACH, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in ...
Seeking Alpha

Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5

WESTLAKE VILLAGE, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in ...
Monthly Prescribing Reference

FDA to Review Roflumilast Cream 0.15% for Atopic Dermatitis

Roflumilast cream is a once-daily, topical phosphodiesterase-4 inhibitor. The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for roflumilast cream 0.15% ...
Nasdaq

Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal ...

WESTLAKE VILLAGE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on immuno-dermatology, today announced ...
Monthly Prescribing Reference

Zoryve Cream 0.15% for Atopic Dermatitis Now Available

Credit: Arcutis. Zoryve cream contains roflumilast, a phosphodiesterase type 4 inhibitor. Zoryve (roflumilast) cream 0.15% is now available for the topical treatment of mild to moderate atopic ...